-
-
-
-
-
-
-
22nd Century Group Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
22nd Century Group (XXII) Reports Q4 Revenue of $7.4M, Net Loss of $22.1M
-
-
-
-
-
-
-
22nd Century Announces Executive Leadership Changes
-
-
-
-
-
-
-
22nd Century Group (XXII) Acquires RX Pharmatech
-
-
-
-
-
-
-
22nd Century Group (Nasdaq: XXII) Begins Integration of GVB Biopharma, Creating a Complete, Robust Hemp/Cannabis Platform
-
-
-
-
-
-
-
Pre-Open Movers 11/21: (AMTD) (PLAN) (SCHW) Higher; (CUB) (BJ) (OPTN) Lower (more...)
-
-
-
-
-
-
-
Pre-Open Movers 10/09: (CLNT) (TROV) (GEVO) Higher; (XXII) (KTWO) (PTCT) Lower (more...)
-
1,202,389 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


